Catherine Fiona Macpherson

Catherine Fiona Macpherson

Auto-generated profile, based on publicly available information

Catherine Fiona Macpherson

Nursing, Seattle Children's Hospital, Seattle, Washington

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CMCatherine Fiona Macpherson
Catherine Fiona Macpherson
LLLauri A. Linder
Lauri A. Linder
SASuzanne Ameringer
Suzanne Ameringer
JEJeanne Erickson
Jeanne Erickson
KSKristin Stegenga
Kristin Stegenga
NWNancy F. Woods
Nancy F. Woods

5 June 2017 in Cancer
Verified
Journal Article
Open access
PDF file
PHPamela S. Hinds
Pamela S. Hinds
JWJichuan Wang
Jichuan Wang
ESEmily Dunn Stern
Emily Dunn Stern
CMCatherine Fiona Macpherson
Catherine Fiona Macpherson
CWClaire M. Wharton
Claire M. Wharton
SJShana Jacobs
Shana Jacobs
BACKGROUND: Pediatric participants on phase 1 or phase 2 clinical trials for incurable cancer are at risk of experiencing toxicities (adverse events [AEs]) related to trial participation. Multiple AEs are subjective; thus, the real impact of trial treatment cannot be known unless patient subjective reports are solicited.METHODS: The authors assessed the feasibility and acceptability of soliciting symptom, function, and quality of life (QOL) reports from participants aged 8 to 18 years who were enrolled on phase 1/2 clinical trials at 4 cancer centers during the first course of chemotherapy. The authors also assessed the reliability and validity of 6 self‐report Patient‐Reported Outcomes Measurement Information System (PROMIS) pediatric measures and 4 open‐ended interview questions at 2 time points (at the time of trial enrollment [T1] and 3 to 4 weeks later [T2]).RESULTS: The enrollment rate of 75.9% (20 participants) exceeded the feasibility criterion, and missingness of measures by person, measure, and items at T1 and T2 were lower than the acceptability criteria. New QOL themes were limited to the impact of treatment on families and being away from home, family, and friends for treatment. All but one measure at T1 met the reliability criterion and all measures did so at T2. Validity support was limited however because as theorized, mobility decreased and fatigue increased as AEs increased.CONCLUSIONS: Soliciting and documenting symptom, function, and QOL reports from patients aged 8 to 18 years who are enrolled on a phase 1/2 clinical trial is feasible and acceptable to participants, particularly when embedded in trials. Reliable and valid findings can result, making patient self‐reported outcomes a possible new trial endpoint. Cancer 2017;123:3799–3806. © 2017 American Cancer Society

1 October 2015 in Menopause
Verified
Journal Article
Closed access
NWNancy Fugate PhD Woods
Nancy Fugate PhD Woods
RIRita Ismail
Rita Ismail
LLLauri Linder
Lauri Linder
CMCatherine Fiona PhD Macpherson
Catherine Fiona PhD Macpherson
Objective: This study aims to elicit midlife women's heuristics about symptom clusters they were experiencing, as identified by the Computerized Symptom Capture Tool for Menopause (C-SCAT M). Methods: Women aged 40 to 60 years who were experiencing symptoms that they associated with menopause were recruited through flyers posted on campus and in clinics. Women completed the C-SCAT M application (app), using an iPad, by identifying and drawing symptom clusters they experienced during the last 24 hours, indicating relationships among symptoms, prioritizing the clusters and symptoms within them, making causal attributions, and identifying exacerbating and ameliorating factors. They were asked to prioritize the clusters and a symptom within each cluster. While women were completing the app, they were asked to “think aloud” about their experience using the app. Data generated from the C-SCAT M app were transmitted securely to an Amazon Web Services account and saved as screen images and Excel files to preserve both graphical images and text elicited from the app. Qualitative data were saved in verbatim phrases. Conventional content analysis was used to analyze qualitative data. Results: Thirty women completed the app. Most women (77%) stated that the final diagrams were very/extremely accurate in depicting their symptoms and their connections. Women reported between 1 and 22 symptoms (median, 11). Hot flashes, waking up during the night, night sweats, and early morning awakening were the most commonly reported symptoms. Women rated hot flashes as their most bothersome symptom, followed by waking up during the night and fatigue. They reported more than 300 different bivariate relationships between their symptoms and more than 150 unique causal paths. They believed that hot flashes caused several symptoms, especially sleep disruption, and most could describe the time order of their symptoms. Women reported clusters consisting of 2 to 18 symptoms. Women also named each cluster based on their response to their symptoms (“really annoying”), time of occurrence (“night problem”), and symptoms included in the cluster (“hot flash”). They attributed their clusters to menopause, life demands, and other symptoms, among other causes. Management strategies that women used included over-the-counter preparations, sleep, rest, and other lifestyle changes. Some women requested for a copy of their final symptom cluster diagram to discuss with their healthcare providers. Conclusions: Use of the C-SCAT M affords women an opportunity to depict their symptoms and clusters and the relationships between them and to provide narrative data about their heuristics. Women's unsolicited comments about using the cluster diagram to facilitate conversations (about their symptoms) with their healthcare providers suggest the potential value of modifying the C-SCAT M and evaluating its use in a healthcare setting.